Clinical trials: Pioglitazone
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether biphasic insulin aspart 70/30 is a safe and at least as effective alternative in combination with two oral anti-diabetics…
- Trial name
- ACTION (NCT00097279)
- Testing
- biphasic insulin aspart, pioglitazone, metformin
- Where
- 73 sites in United States
- Volunteers
- 230 people
- Sponsor
- Novo Nordisk A/S
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
- Trial name
- NCT00839527
- Testing
- albiglutide, metformin, glimepiride
- Where
- 358 sites in United States, Germany and 7 more
- Volunteers
- 685 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy of pioglitazone, twice daily (BID), combined with metformin versus pioglitazone taken alone and metformin taken alone in treating Type 2 Diabetes Mellitus.
- Trial name
- NCT00727857
- Testing
- Pioglitazone and metformin, Pioglitazone, Metformin
- Where
- 77 sites in United States, Chile and 2 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Healthy, Overweight
Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)
The purpose of this study is to evaluate whether 30 mg of pioglitazone administered once daily for up to 28 days to healthy overweight and obese subjects will lead to a significant change in insulin sensitivity, measured in the…
- Conditions
- Healthy, Overweight, Obesity
- Trial name
- NCT01115712
- Testing
- Comparator: Pioglitazone, Comparator: Hyperinsulinemic Euglycemic Clamp
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type2 Diabetes
A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or Pioglitazone 30mg Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled…
- Trial name
- NCT04885712
- Testing
- Metformin≥1000mg, Pioglitazone 15mg, Pioglitazone 30 mg
- Where
- South Korea
- Volunteers
- 378 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with pioglitazone HCl in patients with type 2 diabetes.
- Trial name
- NCT00631007
- Testing
- INT131 besylate, Pioglitazone HCl
- Where
- 66 sites in United States, Mexico
- Volunteers
- 367 people
- Sponsor
- InteKrin Therapeutics, Inc.
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions
Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone hydrochloride and metformin hydrochloride)…
- Trial name
- NCT01800227
- Testing
- Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Type 2 Diabetes
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated with other antidiabetic…
- Trial name
- NCT00143520
- Testing
- Rivoglitazone, Pioglitazone
- Where
- 74 sites in United States
- Volunteers
- 441 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in…
- Trial name
- NCT00814372
- Testing
- MBX-102, Actos, Metformin
- Where
- 26 sites in United States, India
- Volunteers
- 242 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
- Trial name
- NCT05411965
- Testing
- BR3003(T), BR3003B(R1), BR3003C(R2)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus
Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease
The purpose of this study is to evaluate the cardiovascular effects of pioglitazone, once daily (QD), versus glyburide when administered to patients with type 2 diabetes mellitus and mild cardiac disease.
- Trial name
- NCT00521742
- Testing
- Pioglitazone, Glyburide
- Volunteers
- 300 people
- Sponsor
- Takeda
Type II Diabetes
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus
- Trial name
- PIEMONTE (NCT05028140)
- Testing
- PIEMONTE, EMPAGLIFLOZIN, PIOGLITAZONE
- Where
- Brazil
- Volunteers
- 480 people
- Sponsor
- EMS
Type 2 Diabetes
Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of long-term use of Sonias Combination Tablets in patients with type 2 diabetes mellitus in the routine clinical setting.
- Trial name
- NCT02098733
- Testing
- Pioglitazone/glimepiride
- Volunteers
- 1,168 people
- Sponsor
- Takeda
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.
This 3 arm study will assess the efficacy of taspoglutide on glycemic control (as assessed by HbA1c) in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone, compared to placebo after 24…
- Trial name
- NCT00744367
- Testing
- metformin, pioglitazone, taspoglutide
- Where
- 113 sites in United States, Brazil and 7 more
- Volunteers
- 326 people
- Sponsor
- Hoffmann-La Roche
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
This is an open-label, single-sequence, 3-period crossover study conducted in healthy subjects. Eligible subjects will participate in a single treatment period, in which they will receive the following treatments: Day 1, single…
- Trial name
- NCT03457597
- Testing
- Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Mild Cognitive Impairment Due to Alzheimer's Disease
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
The purpose of this study is to evaluate the effect of pioglitazone at 24 months compared with placebo on cognitive decline in high-risk participants who have completed the AD-4833/TOMM40_301 study [NCT01931566] with an…
- Trial name
- NCT02284906
- Testing
- Pioglitazone
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 40 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
Investigate the Effect of AZD1656 on the Pharmacokinetics of Pioglitazone and Vice Versa in Type 2 Diabetes Mellitus
The purpose of this study is to determine whether administration of AZD1656 will affect the pharmacokinetics of Pioglitazone and vice versa in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01082120
- Testing
- AZD1656, Pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AstraZeneca